Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zai Lab Ltd ( (HK:9688) ) has issued an announcement.
Zai Lab Limited has redesignated Leon O. Moulder, Jr. from independent director to director, effective immediately, while he continues to serve on its Research and Development and Commercial Committees. The move underscores the company’s reliance on Moulder’s extensive biopharmaceutical leadership and board experience, with his compensation aligned to its non-employee director policy and his tenure subject to shareholder approval at the next annual general meeting.
The board affirmed that Moulder holds limited equity in the company, has no relationships with major shareholders or management, and is not bound by a long-term service contract. This governance update, which leaves the overall board composition otherwise unchanged, is framed as a routine listing-rule disclosure with no additional matters requiring shareholder attention.
The most recent analyst rating on (HK:9688) stock is a Hold with a HK$15.50 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
More about Zai Lab Ltd
Zai Lab Limited is a biopharmaceutical company incorporated in the Cayman Islands and listed in Hong Kong, focused on developing and commercializing innovative medicines. The company operates with a board that combines scientific, commercial and investment expertise to support its research, development and commercialization strategy in global healthcare markets.
Average Trading Volume: 10,478,187
Technical Sentiment Signal: Sell
Current Market Cap: HK$15.41B
For detailed information about 9688 stock, go to TipRanks’ Stock Analysis page.